Hereditary Neuropathy Foundation is ranked #32 of 39 medical research organizations in New York, NY, with an America's Best Score of 64 out of 100, based on its 2025 Form 990.
Hereditary Neuropathy Foundation is a 501(c)(3) organization, classified under Medical Research (NTEE H129). Contributions are tax-deductible.
1641 3Rd Ave, New York, NY 10128-3623
Among the 61 scored medical research organizations in New York, Hereditary Neuropathy Foundation holds 13.5 months of operating reserves (peer median 13.5 months), runs a typical yearly deficit of 14.6% (peers: surplus of 3.4%), and has grown spending 5.6% a year (peers: grown spending 7.0% a year).
In fiscal year 2025 it reported $545,418 in revenue and $894,903 in expenses, with contributions making up 106.8% of revenue.
Hnf, inc., a non-profit dedicated to supporting projects through the therapeutic research in accelerated discovery (triad)program, a collaborative effort with academia, government and industry, to develop treatments for cmt. Currently triad involves many groups that span the drug discovery, drug development, and diagnostics continuum. Education and support of the cmt community to improve quality of life is also a key component of hnf's mission.
Main program · fiscal year 2025
Research programs are as follows: Therapeutic research in accelerated discovery (triad) continues to serve as hnf's primary translational research accelerator, supporting the development of essential research tools (including ipscs and animal models), therapeutic candidates, drug screening initiatives, gene therapy programs, and digital health technology innovations. The program maintains strong p… Read more
Research programs are as follows: Therapeutic research in accelerated discovery (triad) continues to serve as hnf's primary translational research accelerator, supporting the development of essential research tools (including ipscs and animal models), therapeutic candidates, drug screening initiatives, gene therapy programs, and digital health technology innovations. The program maintains strong partnerships with academic institutions, regulatory agencies, and industry collaborators and advances key scientific initiatives in biomarker development, clinical endpoint refinement, and therapy translation. Triad also leads the annual cmt clinical trial readiness summit, which brings together global experts to align on regulatory expectations, optimize trial design, and accelerate therapy development. The global registry for inherited neuropathies (grin) continues to grow as an international cmt patient registry, capturing natural history data and providing comprehensive patient-reported, clinical, digital, and genetic datasets. Grin plays a critical role in clinical trial readiness, supporting feasibility assessments, endpoint development, and patient recruitment for therapeutic development programs. Grin insights and data infrastructure inform key sessions and working groups at the cmt clinical trial readiness summit, helping researchers and industry partners address unmet needs and strengthen future trial strategies. The cmt biobank continues to expand its patient sample collection, including blood, saliva, tissue, skin fibroblasts, ipscs, and other biospecimens donated by individuals with cmt. These samples are processed and stored under strict quality-controlled protocols and remain securely linked to grin clinical, digital, and genetic data. This integrated resource supports pre-competitive biomarker discovery, molecular research, and digital biomarker validation, enabling researchers and industry partners to accelerate therapeutic development. Findings and collaborative opportunities from the biobank are regularly highlighted at the cmt clinical trial readiness summit, where cross-sector partners align on biomarker priorities and strategies to advance future treatments.
$805,802 spent
Where each dollar went · fiscal year 2025
Of every dollar it spent, 90¢ went to programs, 6¢ to management and 4¢ to fundraising.
Programs $805,802
Management $55,157
Fundraising $33,944
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Spending on programs Not scored; America's Best needs 65%+
90%
Meets
Compared with New York peers
Measure
This organization
Peer median
Operating reserves
13.5 mo
13.5 mo
Typical margin
−14.6%
+3.4%
Spending growth
+5.6% / yr
+7.0% / yr
Debt load
0.6%
13.5%
Peers: the 61 New York medical research organizations with a score, ranked or below the bar.
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$545,418Fiscal year 2025
Expenses$894,903Fiscal year 2025
Total assets$1,016,066Fiscal year 2025
Total liabilities$6,182Fiscal year 2025
Fiscal year ending June2025
Revenue$545,418
Expenses$894,903
Net income−$349,485
Net assets$1,009,884
Notable sources of revenue
Percent of total revenue
Contributions
$582,345
106.8%
Program services
$0
0.0%
Investment income
$5,908
1.1%
Other (net)
−$42,835
−7.9%
Assets / debt
Total assets
$1,016,066
Total liabilities
$6,182
Net assets
$1,009,884
Compensation
Not in our extract for this year.
Fiscal year ending June2024
Revenue$655,296
Expenses$730,003
Net income−$74,707
Net assets$1,441,198
Notable sources of revenue
Percent of total revenue
Contributions
$713,969
109.0%
Program services
$0
0.0%
Investment income
$5,540
0.8%
Other (net)
−$64,213
−9.8%
Assets / debt
Total assets
$1,503,541
Total liabilities
$62,343
Net assets
$1,441,198
Compensation
Not in our extract for this year.
Fiscal year ending June2023
Revenue$543,625
Expenses$671,491
Net income−$127,866
Net assets$1,503,166
Notable sources of revenue
Percent of total revenue
Contributions
$559,719
103.0%
Program services
$0
0.0%
Investment income
$5,104
0.9%
Other (net)
−$21,198
−3.9%
Assets / debt
Total assets
$1,515,448
Total liabilities
$12,282
Net assets
$1,503,166
Compensation
Officers and key employees
$66,346
Share of expenses
9.9%
Fiscal year ending June2022
Revenue$1,259,879
Expenses$759,374
Net income$500,505
Net assets$1,621,464
Notable sources of revenue
Percent of total revenue
Contributions
$1,159,086
92.0%
Program services
$0
0.0%
Investment income
$1,424
0.1%
Other (net)
$99,369
7.9%
Assets / debt
Total assets
$1,627,053
Total liabilities
$5,589
Net assets
$1,621,464
Compensation
Officers and key employees
$60,000
Share of expenses
7.9%
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?